PDCD1 and type 1 diabetes mellitus: Similarly, it has been reported that PD-1/PD-L1 inhibitors cause hypopituitarism in less than 1%, hypothyroidism in 5.9%, hyperthyroidism in 1.0-4.7%, insulin-dependent diabetes in 0-1%, and adrenocortical hypofunction in less than 2% (1).